Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial.
Jordan KraaijenhofMarcel H A MuskietLennart TonneijckD Margriet OuwensMark H H KramerDaniël H van RaalteMathijs C BunckPublished in: Diabetes, obesity & metabolism (2020)
When compared with glimepiride, linagliptin does not affect fasting blood pressure. However, linagliptin blunted the postprandial drop in SBP, which could benefit patients with postprandial hypotension.